Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry.
暂无分享,去创建一个
G. Raskob | R. Benza | R. Barst | D. Badesch | A. Frost | M. Mcgoon | T. Liou | H. Farber | C. Elliott | M. Turner | K. Feldkircher | A. Krichman | Scott Giles | Dave P. Miller | C. G. Elliott | Dave P. Miller | D. Miller | Dave P. Miller | R. Barst | M. McGoon
[1] W. Cornwell,et al. Pulmonary arterial hypertension. , 2011, Current problems in cardiology.
[2] G. Raskob,et al. 397: REVEAL Registry: Pediatric IPAH Versus Pediatric Pulmonary Vascular Disease Associated with Congenital Heart Disease , 2009 .
[3] G. Raskob,et al. 708: REVEAL Registry: Comparison of Patients with Childhood-Onset and Adult-Onset Pulmonary Vascular Disease Associated with Congenital Heart Disease , 2009 .
[4] G. Raskob,et al. 228: REVEAL Registry: Comparison of Patients with Childhood-Onset and Adult-Onset Idiopathic Pulmonary Arterial Hypertension , 2009 .
[5] M. Cheitlin. Addition of Sildenafil to Long-Term Intravenous Epoprostenol Therapy in Patients with Pulmonary Arterial Hypertension: A Randomized Trial , 2009 .
[6] G. Raskob,et al. A COMPARISON OF REVEAL REGISTRY DEMOGRAPHIC DATA WITH OTHER/PRIOR REGISTRIES OF PULMONARY ARTERIAL HYPERTENSION (PAH) , 2008 .
[7] G. Raskob,et al. Design of the REVEAL registry for US patients with pulmonary arterial hypertension. , 2008, Mayo Clinic proceedings.
[8] K. Lewis. Pulmonary Arterial Hypertension in France: Results from a National Registry , 2007 .
[9] D. Badesch,et al. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. , 2007, Chest.
[10] R. Barst,et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. , 2006, American journal of respiratory and critical care medicine.
[11] C. Ricachinevsky,et al. Treatment of pulmonary arterial hypertension. , 2006, Jornal de pediatria.
[12] L. Abenhaim,et al. Temporal trends and drug exposures in pulmonary hypertension: an American experience. , 2006, American heart journal.
[13] R. Barst,et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. , 2006, Journal of the American College of Cardiology.
[14] T. Fleming,et al. Sildenafil citrate therapy for pulmonary arterial hypertension. , 2005, The New England journal of medicine.
[15] D. Badesch,et al. Evaluation and Management of the Patient with Pulmonary Arterial Hypertension , 2005, Annals of Internal Medicine.
[16] D. Badesch,et al. Ambrisentan therapy for pulmonary arterial hypertension. , 2005, Journal of the American College of Cardiology.
[17] A. Torbicki,et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension , 2004 .
[18] Horst Olschewski,et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. , 2004, European heart journal.
[19] L. Rubin. Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. , 2004, Chest.
[20] D. Mccrory,et al. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. , 2004, Chest.
[21] D. Mccrory,et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. , 2004, Chest.
[22] R. Dixon,et al. Sitaxsentan therapy for pulmonary arterial hypertension. , 2004, American journal of respiratory and critical care medicine.
[23] W. Seeger,et al. Clinical classification of pulmonary hypertension. , 2001, Clinics in chest medicine.
[24] D. Mccrory,et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. , 2004, Chest.
[25] P. Kao,et al. High prevalence of autoimmune thyroid disease in pulmonary arterial hypertension. , 2002, Chest.
[26] S. Rich,et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. , 2002, American journal of respiratory and critical care medicine.
[27] Orris,et al. INHALED ILOPROST FOR SEVERE PULMONARY HYPERTENSION , 2002 .
[28] Avid,et al. BOSENTAN THERAPY FOR PULMONARY ARTERIAL HYPERTENSION , 2002 .
[29] R. Speich,et al. Clinical classification of pulmonary hypertension. , 2004, Journal of the American College of Cardiology.
[30] A. Kashyap,et al. Thyroid disease and primary pulmonary hypertension. , 2001, JAMA.
[31] G. Simonneau,et al. EFFECTS OF THE DUAL ENDOTHELIN RECEPTOR ANTAGONIST BOSENTAN IN PATIENTS WITH PULM HT: A RANDOMIZED PLACEBO CONTROLLED STUDY , 2001 .
[32] C. Campo López,et al. [Hyperthyroidism and pulmonary hypertension]. , 2001, Revista clinica espanola.
[33] A. Arroliga,et al. Primary pulmonary hypertension and thyroid disease. , 2000, Chest.
[34] Stuart Rich,et al. Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease , 2000, Annals of Internal Medicine.
[35] S. Schneeweiss,et al. Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension. , 2000, Chest.
[36] A. Arroliga,et al. High prevalence of hypothyroidism in patients with primary pulmonary hypertension. , 1999, The American journal of the medical sciences.
[37] L. Rubin,et al. Primary pulmonary hypertension. , 1997, The New England journal of medicine.
[38] J. Madans,et al. Use of postmenopausal hormone replacement therapy: estimates from a nationally representative cohort study. , 1997, American journal of epidemiology.
[39] B. Groves,et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. , 1996, The New England journal of medicine.
[40] D. Wysowski,et al. Use of Menopausal Estrogens and Medroxyprogesterone in the United States, 1982–1992 , 1995, Obstetrics and gynecology.
[41] B. Groves,et al. Hypothyroidism and Primary Pulmonary Hypertension: An Autoimmune Pathogenetic Link? , 1993, Annals of Internal Medicine.
[42] E H Bergofsky,et al. Survival in Patients with Primary Pulmonary Hypertension: Results from a National Prospective Registry , 1991 .
[43] E H Bergofsky,et al. Primary pulmonary hypertension. A national prospective study. , 1987, Annals of internal medicine.